30 C
Vientiane
Saturday, May 10, 2025
spot_img
Home Blog Page 505

Digital Garden Tokyo to Feature Unprecedented Speaker Lineup and Over 80 Companies Represented by C-Suite Delegations at Japan’s First Global-Scale Digital Infrastructure Summit

TOKYO, March 4, 2025 /PRNewswire/ — With just two weeks until the highly anticipated Digital Garden Tokyo, excitement is building for Japan’s inaugural global-scale digital infrastructure summit. Taking place on March 17-18, 2025, at Toranomon Hills Forum, the event will bring together over 80 companies, primarily represented by C-suite delegations, including leading investment firms, operators, hyperscalers, cloud providers, end users, and industry leaders. This pivotal gathering will provide a broad perspective on the future of digital infrastructure.

The speaker lineup includes Yasutoshi Nishimura, member of the House of Representatives and former Minister of Economy, Trade, and Industry (METI), who will share insights into Japan’s digital infrastructure strategy and global positioning.

A highlight of the summit will be the Government Panel, featuring senior leaders from Japan’s key policymaking bodies, offering a unified view of digital infrastructure policy. Panelists include:

  • Sachio Muto, Director, International and Digital Policy (IDP) Division, City Bureau, MLIT
  • Kazuhiro Wakatsuki, Chief Director, Digital Agency
  • Takuya Watanabe, Director, Software & Information Service Industry Strategy Office, METI

These experts will provide valuable perspectives on Japan’s digital policies, future strategies, and collaborative efforts shaping the sector.

The summit will also feature senior executives and regional leaders from major digital infrastructure organizations. Confirmed speakers include leaders from:

Ada Infrastructure, AirTrunk, COLT DCS, Cushman & Wakefield, CyrusOne, DigitalBridge, DigitalEdge, Gaw Capital, Greenberg Traurig, Kansai Electric, Mercari, Morrison Foerster, PGIM, SMBC, SoftBank Group, ST Telemedia, University of Tokyo, and more.

These executives will discuss key industry trends, innovations, and strategies driving the sector forward.

The summit’s Gala on the first evening will gather top stakeholders to foster collaboration, build partnerships, and drive transactions in the digital infrastructure space.

Bringing together top executives, thought leaders, and policymakers, the event will create a dynamic environment for discussions on pressing challenges and opportunities, from government policy to investment and technology.

“We’re thrilled to convene such an exceptional group of leaders across the digital infrastructure sector,” said Daniel Cox, Executive Chairman of Digital Garden Tokyo. “With C-suite executives, government representatives, and industry innovators in one place, this summit will foster collaboration and shape the future of digital infrastructure in Japan and across the region.”

Digital Garden Tokyo promises unparalleled networking, cutting-edge insights, and critical discussions. Don’t miss this key moment in Japan’s digital infrastructure evolution.

For details and registration, please visit www.digitalgarden.co.jp.

CONTACT: media@digitalgarden.co.jp

Binance Supports Global Fintech Institute to Advance Fintech Education in the AI & Crypto Era

TOKYO, March 4, 2025 /PRNewswire/ — Binance, the global blockchain ecosystem behind the world’s largest cryptocurrency exchange, has announced its sponsorship and strategic support for the Global Fintech Institute (GFI) to advance fintech education, professional development and innovation. This collaboration aims to equip professionals with the skills needed to thrive in an era defined by artificial intelligence (AI), blockchain, and evolving financial regulations.

Empowering the Fintech Workforce for a Digital Future

As part of this initiative, Binance is excited to sponsor over 500 scholarships for GFI’s latest course, Foundation in Crypto Regulation and Compliance. The course is catered for professionals in regulatory bodies, financial institutions, and compliance roles, especially those with a passion and curiosity for crypto.

Designed by leading industry experts and academics, this 16-hour online program provides regulators and compliance professionals with a comprehensive understanding of blockchain, cryptocurrency, and financial regulations. Participants will also gain hands-on insights into numerous important areas such as AML/KYC compliance and financial crime prevention, blockchain forensics and cross-border regulatory frameworks, RegTech solutions, and more. By the end of the course, attendees will be well-equipped to tackle compliance challenges, mitigate risks, and adapt to the evolving crypto landscape.

Interested professionals can apply for the scholarship at: https://share.hsforms.com/2LlwvBcnnTRGy1PXrfnzKCg5nir0

Importance of Fintech Education in a Transformative Era

Through this strategic collaboration, Binance and GFI aim to equip professionals with expertise in AI-driven finance and digital assets, develop fintech training programs, advance research, host industry events, and enhance global fintech literacy.

Richard Teng, CEO of Binance, commented on the partnership: “We are thrilled to join forces with the Global Fintech Institute to advance fintech education in this transformative era of AI and cryptocurrency. Education plays a crucial role in closing the knowledge gap for blockchain and crypto, just as it has for other emerging technologies in the past. Today’s announcement underscores Binance’s commitment to fostering innovation, enhancing regulatory compliance, and ensuring that the global fintech workforce is future-ready. With the ever-rising interest and popularity of crypto, we are certain that crypto-focused courses like these would be in high demand, and we look forward to welcoming interested applicants.”

Professor David Lee, Founding Chairman at GFI, added: “As AI, blockchain, and digital assets continue to transform the financial landscape, there is an urgent need for structured fintech education and informed policy discussions. The rapid pace of technological advancement demands that professionals, regulators, and institutions stay ahead of emerging trends to ensure financial stability, security, and innovation-driven growth. Binance’s generous support allows us to expand our educational programs, conduct critical research, and foster industry-wide collaboration. This partnership enables us to bridge the knowledge gap between traditional finance and digital innovations, equipping professionals with the expertise to navigate regulatory challenges, harness new opportunities, and drive responsible adoption of cutting-edge financial technologies.”

The Policy Shift & Its Impact on Fintech

The growing political endorsement of digital assets in many key markets globally signals a significant policy shift that could accelerate institutional adoption, regulatory clarity, and the integration of blockchain technology into mainstream finance. If pro-crypto policies gain traction, we could see:

  • More financial institutions embracing Bitcoin, stablecoins, and tokenized assets.
  • Regulatory clarity attracting global investments into fintech startups and digital finance.
  • AI-powered DeFi and blockchain-based financial services gaining wider acceptance, transforming traditional banking.

This partnership between Binance and GFI ensures that compliance and regulation professionals are well-equipped to capitalize on these emerging opportunities by providing cutting-edge training, research, and thought leadership.

The collaboration between Binance and GFI was first announced at GFTN Forum, Japan 2025. Both Binance and GFI are proud members and partners of the GFTN network.

About Binance

Binance is a leading global blockchain ecosystem behind the world’s largest cryptocurrency exchange by trading volume and registered users. Binance is trusted by more than 260 million people in 100+ countries for its industry-leading trading engine speed, protections for investors, and unmatched portfolio of digital asset products and offerings from trading and finance to education, research, social good, payments, institutional services, and Web3 features. Binance is devoted to building an inclusive crypto ecosystem to increase the freedom of money and financial access for people around the world with crypto as the fundamental means.

For more information, visit: https://www.binance.com

About Global Fintech Institute

Global Fintech Institute (GFI) is a not-for-profit think tank and certification body dedicated to advancing fintech education, fostering meaningful collaboration, and promoting professional excellence across regulatory bodies, corporations, and academic institutions. Headquartered in Singapore, GFI tackles key challenges in the fintech landscape through rigorous research, insightful whitepapers, and thought leadership discussions which influence policy and set industry standards.

Analytic Edge Now a Certified Partner in APAC for Google’s Meridian Marketing Mix Modelling (MMM) Platform

SINGAPORE, March 4, 2025 /PRNewswire/ — Analytic Edge (a C5i company), a leading provider of marketing and sales analytics solutions, announced that it is now a certified partner in APAC for Google’s Meridian Marketing Mix Modelling (MMM) platform. Meridian is an open-source MMM platform built by Google to help advertisers measure the impact of their marketing spends on sales and make smarter, data-driven decisions on marketing strategy and budgets.

For the Meridian partnership, Analytic Edge will serve as a consulting and modelling partner to help Google’s advertisers develop MMMs using Meridian. This is particularly useful for advertisers as they can leverage Analytic Edge’s expertise gained from delivering 3000+ MMMs globally over the past 3 years across multiple domains. Advertisers can also tap into a ready pool of Analytic Edge’s data scientists and analysts who are certified on Meridian.

Analytic Edge has worked closely as a Measurement Partner to Google for several years, including delivering multiple MMMs for its own advertisers. The MMMs were delivered using Analytic Edge’s always-on MMM platform, Demand Drivers.

Commenting on the partnership, Santosh Nair, Co-Founder and Director, Analytic Edge, said, “Analytic Edge is excited to apply our extensive MMM experience and to partner with Google on Meridian. Meridian integrates technical innovations to assess the indirect impact of search on marketing channels in the consumer journey. It enhances the measurement of “Reach” and “Frequency” for YouTube campaigns, helping advertisers with campaign planning. The seamless integration with Google MMM Data Platform boosts productivity in data processing and improves the accuracy of the data used in the model. Our collaboration on Meridian will help advertisers better understand the interactions between channels and improve their campaign strategies.”

About Analytic Edge

Analytic Edge, a part of C5i, is a global analytics company that leverages technology and advanced analytics to help companies make data-based marketing decisions. The company’s flagship platform Analytic Edge Qube offers a suite of marketing analytics solutions with a Software as a Service (SaaS) model. The solutions include Demand Drivers, SynTest, PriceSense and PowerView. Analytic Edge works with clients across industry verticals such as e-commerce, mobile apps, gaming, consumer packaged goods, retail, automotive and many others. The company has a presence in Singapore, India, US, Mexico, Brazil, UK, Switzerland, China, Japan, South Korea, UAE and Australia. For more information, visit www.analytic-edge.com 

Media Contact:

Megha Chaudhry

Vice President

Global Head of Marketing & Alliance Management, C5i

O: +1 (425) 615 7474 | E:  megha.chaudhry@c5i.ai

 

 

 

Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction (“double chin”)

REROVOT, Israel, March 4, 2025 /PRNewswire/ — Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation in China for the treatment of fat reduction in the submental area. Submental fat (SMF) reduction is the first indication for RZL-012 among many potential aesthetic focal fat reduction treatments for body shaping.

RZL-012 is an injectable lipolytic drug being developed for the reduction of unwanted submental fat (“double-chin”) or fat in other body areas, in adults. The compound is injected subcutaneously into submental fat tissue in 1-2 injection sessions by trained physicians and destroys fat cells, resulting in fat volume reduction and improved appearance of the injected area. 

Raziel Therapeutics and Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK), partnered with Raziel Therapeutics to develop RZL-012 and JuveStar holds the commercial rights for RZL-012 in Greater China. A phase 3 study will be initiated in China during the upcoming few weeks. JuveStar will be responsible for conducting the phase 3 study, while Raziel will be responsible for manufacturing the drug substance and finished drug product for the clinical activities in China. The product is expected to be launched in China during 2027. “The initiation of phase 3 study in the China market is a significant progress, we believe that RZL 012 will be a lead drug for focal fat reduction in China” said Alon Bloomenfeld Founder and CEO of Raziel therapeutics. 

Fosun Pharma is one of the leading healthcare companies in China, with expertise and access to both the aesthetic and therapeutic markets. The collaboration will enrich Fosun Pharma’s pipeline in the field of medical aesthetics and provide more options for the unmet clinical needs. The market for focal reduction of resistant fat based therapies, has high potential and is complementary to the widespread use of weight loss therapies. The benefit of using RZL-012 is its ability to target focal or localized unwanted fat with only 1-2 treatment cycles.

About Submental Fullness

Submental fullness is a common yet undertreated condition that can detract from an otherwise balanced and harmonious facial appearance – leading to an older and heavier look. Submental fullness can affect adults – both women and men – of all ages, weights and genders. Influenced by multiple factors including aging and genetics, submental fullness is often resistant to diet and exercise.

About RZL – 012

RZL-012 is a novel small molecule entity formulated with no human and no animal related components. When injected into subcutaneous fat, RZL-012 destroys fat cells and reduces fat volume. Once destroyed, those cells can no longer store or accumulate fat.

About Fosun Pharma:

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of “Innovation for Good Health”, continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation.

For more information, please visit: www.fosunpharma.com.

About Raziel Therapeutics.

Raziel Therapeutics is an emerging Israeli based pharmaceutical leader developing a disruptive technology for the treatment of aesthetic indications. Raziel has developed a unique proprietary compound by obtaining a License from the Hebrew university.  The company’s lead compound, RZL-012, is in phase 2 or 3 clinical development for a broad range of aesthetic indications. More information on Raziel Therapeutics may be found at https://raziel-therapy.com/

Contact:
Alon Bloomenfeld
alon@raziel-therapy.com
+972542325070

WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production

–          EffiX™ is designed to meet the industry’s demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe

–          EffiX™ delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA

HANGZHOU, China, March 4, 2025 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of its innovative technology platform, EffiX™, a proprietary E. coli expression system engineered to deliver high yield and exceptional stability in the production of recombinant proteins and plasmid DNA.

The global market for microbial-derived products and intermediates is expanding rapidly, driven by increasing demand for smaller complex biomolecules — such as antibody fragments, nanobodies, enzymes, cytokines, various antigens, polypeptides, and plasmid DNA (pDNA) — all of which present significant opportunities for the development of next-generation therapies. To address the challenges in producing these biomolecules, WuXi Biologics has introduced the EffiX™ platform, which enables the development and manufacturing of microbial-derived biologics with high yield, consistent quality, as well as superior stability and scalability. The EffiX™ platform achieves titers exceeding 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.

With streamlined processes tailored to accommodate a diverse range of project requirements from research through commercial manufacturing, the EffiX™ platform accelerates the advancement of innovative biotherapeutics for global partners by offering a comprehensive and cost-effective Chemistry, Manufacturing, and Controls (CMC) strategy.

Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are excited to upgrade our microbial solutions with the innovative EffiX™ platform, which offers our clients exceptional productivity and product quality, along with scalability and flexibility at every stage of development. WuXi Biologics’ continual launching of new technology platforms stems from our drive to push boundaries and foster innovation – all with the goal of enabling our global partners to accelerate the delivery of more high-quality and affordable biologics to patients worldwide.”

The EffiX™ platform is an integral component of a broader integrated technology platform at WuXi Biologics, which is predicated on microbial expression systems. This comprehensive platform encompasses early-stage research, CMC development, and GMP manufacturing, facilitating faster, more efficient, and cost-effective manufacturing processes for various modalities in the realm of next-generation therapies.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Business
info@wuxibiologics.com

Media
PR@wuxibiologics.com

Huawei Launches AI-Ready Data Storage for Carriers to Embrace AI

BARCELONA, Spain, March 4, 2025 /PRNewswire/ — At MWC 2025 Barcelona, Dr. Peter Zhou, President of Huawei Data Storage Product Line, delivered a keynote speech on AI-Ready Data Storage Accelerates Telco-to-Techco Transformation. The speech, delivered at the product and solution launch event.

Peter Zhou, President of Huawei Data Storage Product Line, delivered a keynote speech
Peter Zhou, President of Huawei Data Storage Product Line, delivered a keynote speech

Dr. Peter Zhou believes the AI-powered transformation of various industries is creating a golden era for data. Global carriers are continuously exploring business value by capitalizing on and monetizing application scenarios, such as smart home and digital factories. And that means higher demands on data storage, service capabilities, and business models.

To address these challenges, “Huawei Data Storage provides the AI-Ready data lake solution, diverse data storage services, and the FlashEver business model, empowering carriers to turn their disordered data into high-quality assets to unlock the value of data,” as Dr. Peter Zhou said.

  • The AI-Ready data lake breaks data silos, making data visible, manageable, and available

For mission-critical production workloads, Huawei launches the New-Gen OceanStor Dorado Converged All-Flash Storage and OceanStor A Series High-Performance AI Storage. These solutions boast 100 million–level IOPS, financial-grade reliability, and efficient AI training and inference, supporting tens of billions of daily charging services and robust mobile financial services. Further, the enhanced object storage enables seamless integration of carrier services with cloud-native and AI applications.

For mass data, the Huawei New-Gen OceanStor Pacific All-Flash Scale-Out Storage provides industry-high density and low power consumption. The storage provides exabyte-level scalability to handle cost pressure from emerging services like live streams and XR games.

Another new offering is the New-Gen OceanProtect All-Flash Backup Storage for data protection. The storage offers five times faster data recovery than industry alternatives, accommodating service needs such as emergency drills and AI application development to protect the value of every bit.

  • Diverse data storage services are fueling carrier AI evolution

Carriers face several challenges in adopting AI, including weak data engineering, inadequate efficient AI model development platforms, long data preparation times, slow model training, and complex AI application development. The Huawei DCS AI Solution provides a one-stop AI full-process toolchain and containerized environment, accelerating fine-tuning and large-scale deployment of AI models.

  • FlashEver business model maximizes carrier investment

Changes in services and technologies are placing greater investment demands on carriers. Dr. Peter Zhou shared FlashEver, the business model that protects investments, providing an evolutionary, flexible architecture to enable seamless upgrades for live-network equipment. Also, Huawei storage platform services offer flexible purchase options, SLA assurance, and diverse storage and data services, ensuring high-quality customer experiences.

Dr. Peter Zhou reaffirmed Huawei’s commitment to continuous innovation, specifically building the AI-ready data storage foundation and future-proof storage power to fuel the AI adoption across the carrier industry.

 

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody

SUZHOU, China, March 4, 2025 /PRNewswire/ –CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global multicenter Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, with no infusion reactions or other adverse events observed.

This trial aims to evaluate the clinical potential of CS2009 in a wide range of advanced solid tumors including, but not limited to, non-small cell lung cancer, hepatocellular carcinoma, gastric adenocarcinoma, endometrial cancer, ovarian cancer, renal cell carcinoma, and cervical cancer, in efforts to advance the development of innovative tumor immunotherapies.

CS2009, an innovative trispecific antibody designed and developed by CStone, combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—and exerts multidimensional anti-tumor effects through synergistic actions. Specifically, anti-PD-1 activity that reverses T cell exhaustion, anti-CTLA-4 activity that promotes T cell activation and proliferation, while anti-VEGFA activity blocks tumor angiogenesis and improves the tumor micro-environment (TME). In the TME, anti-PD-1 and anti-CTLA-4 activities are significantly enhanced by crosslinking with VEGFA. Meanwhile, CS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells while minimizing interference with CTLA-4 regulation in peripheral T cells, thus potentially offering enhanced efficacy with lower systemic toxicity.

In preclinical studies, CS2009 demonstrated superior anti-tumor activity compared to potential competitors. By combining CTLA-4 inhibition with PD-1 and VEGFA blockade, CS2009 may further enhance benefits for patients with low or negative PD-L1 expression, who respond poorly to PD-(L)1 therapies. This well positions CS2009 as a next-generation, first- or best-in-class immunotherapy backbone, with the potential to replace current anti-PD-(L)1-based therapies.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated, “The initiation of the first-in-human study for CS2009 marks a breakthrough in our clinical development. Our robust preclinical data have confirmed CS2009’s potential across a wide range of solid tumor indications. In in vitro studies, CS2009 demonstrated its ability to effectively and specifically activate tumor-infiltrating T cells, as well as robust synergistic effect with anti-VEGF activity; in immunocompetent mouse models, CS2009 showed stronger anti-tumor effects than both PD-1/CTLA-4 and PD-1/VEGF bispecific antibodies; and in toxicology studies, CS2009 exhibited a safety margin which was greater than the PD-1/CTLA-4 bispecific antibody and comparable to the PD-1/VEGF bispecific antibody. These results give us confidence in CS2009’s clinical potential. We look forward to sharing additional clinical data that will further validate its safety and anti-tumor activity, paving the way for a new era in cancer immunotherapy.”

Dr. Qingmei Shi, Chief Medical Officer of CStone, added, “We are pleased to achieve the first-patient-dosed milestone for CS2009, an innovative trispecific antibody that can potentially offer balanced efficacy and safety while addressing the unmet medical needs in patients with low or negative PD-L1 expression. We expect to see rapid and encouraging progress in this study and are committed to bringing improved treatment options to patients with solid tumors worldwide. We appreciate the exceptional efforts of our clinical team, who managed through the entire process—from submitting the clinical trial application in Australia to dosing the first patient—in two months that overlapped with major holidays in China and Australia. This is another testament to CStone’s outstanding clinical development efficiency and unwavering commitment to serving patients.”

Currently, the multicenter Phase I clinical trial of CS2009 is being conducted in Australia, with plans to expand into China and the United States in the near future.

About CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, with the potential to be first- or best-in-class for major tumor types. Its differentiated molecular design combines three clinically validated targets, preferentially invigorating exhausted tumor infiltrating lymphocytes (TILs) while demonstrating VEGF neutralization comparable to existing anti-VEGF antibodies. CS2009 covers a wide range of cancers, including but not limited to non-small cell lung cancer, hepatocellular carcinoma, gastric adenocarcinoma, endometrial cancer, ovarian cancer, renal cell carcinoma, and cervical cancer.

In November 2024, CStone presented preclinical data for CS2009 at the 39th SITC Annual Meeting. These results show that CS2009 exhibits superior anti-tumor activity compared to potential competitors, including PD-1/CTLA-4 bispecific antibodies, PD-1/VEGF bispecific antibodies, and PD-1/CTLA-4 combination therapies.

About CStone 

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit www.cstonepharma.com.   

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

  

Mass production of high-quality, self-standing, large-diameter single-crystal (111) diamond substrates within reach

Development of n-Type Diamonds for Practical Use in Diamond Semiconductors also Making Advances

TOKYO, March 4, 2025 /PRNewswire/ — Orbray has developed production technology for the world’s largest self-standing single-crystal (111) diamond substrates, measuring 20mm square. This achievement marks significant steps in advancing diamond-based quantum devices and power devices. The company aims to commercialize large (111) diamond substrates by 2026 and is also actively working on the development of n-type self-standing diamond substrates, a crucial component for making diamond semiconductor devices mainstream.

Figure: Freestanding 20mm square single-crystal (111) diamond substrate.
Figure: Freestanding 20mm square single-crystal (111) diamond substrate.

Diamond semiconductors are being developed for a wide range of applications due to their exceptional properties. In recent years, there has been significant progress in increasing the size and improving the quality of diamond substrates to meet growing industry demand. High-quality (111) diamond substrates have drawn particular interest in the development of diamond quantum devices that contain nitrogen-vacancy (NV) centers. Additionally, (111) diamond substrates are regarded as essential not only for quantum applications but also for achieving high-performance n-type diamond-based devices, including diamond power devices. However, until now, only small-scale (111) diamond substrates, approximately 3mm square, have been available. (111) diamond crystals were prone to defects known as twin crystals during CVD growth, posing significant challenges to the production of large-diameter and thick single-crystal diamond crystals.

In a September 9, 2021 press release, Orbray Co., Ltd., announced the successful development of a high-quality, 2-inch diameter (100) self-standing diamond substrate using its proprietary efficient step-flow growth method (https://orbray.com/magazine_en/archives/811https://orbray.com/magazine_en/archives/1401). Building on this diamond crystal growth technology and utilizing specially designed sapphire substrates, the company has been advancing the development of a (111) single-crystal diamond self-standing substrate.

This work has culminated in the successful synthesis of a 20mm square (111) single-crystal diamond self-standing substrate without twin defects.

Orbray plans to commercialize this technology by 2026. This advancement is expected to drive progress in the development of diamond semiconductor devices.

Publications related to research results

March 15, 2025, The Japan Society of Applied Physics (JSAP) Spring Meeting: “Large-Diameter (111)-Plane Diamond Free-Standing Crystal Growth”

May 11-15, 2025, International Conference on New Diamond and Nano Carbons: “World-first self-standing (111) heteroepitaxial diamond without twin grown on sapphire substrate”

Orbray Co., Ltd., founded in 1939, specializes in precision jewel parts, small DC motors, and medical equipment, blending cutting-edge technology with craftsmanship. Based in Tokyo, Japan.

Contact

Orbray Co., Ltd., Diamond Division
TEL:+81-3-3919-0101 E-mail:diamond-sales@orbray.com